Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Betaferon

- PMLiVE

France investigates Bayer’s acne drug Diane 35 after deaths

Linked to blood clots in women

- PMLiVE

NICE metrics flawed and should not be used, says EU study

ECHOUTCOME criticises used of quality adjusted life years in HTAs

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price

Novartis building

Novartis expects tough 2013 before a return to growth

Says it will take a year for new medicine sales to overcome Diovan patent loss

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Novartis day

Novartis gets EU approval for Bexsero meningitis B shot

Offers protection for all ages above two months

- PMLiVE

NICE consults on what makes good social care

Citizens Council gives views as UK agency prepares to expand its remit

- PMLiVE

Novartis’ eye drug Jetrea recommended for EU approval

Set to become first drug treatment for sight-threatening condition vitreomacular traction and macular hole

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Interview: Elmar Schnee, Cardiorentis

The former CEO of Merck Serono explains his decision to move to a smaller start-up making big advances in acute heart failure

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links